ADGRE1 antag 
Welcome,         Profile    Billing    Logout  
  Companies    Products    Diseases    Trials    News 
  • ||||||||||  lenzilumab (KB003) / Humanigen, HGEN005 / Humanigen, ifabotuzumab (KB004) / Humanigen
    Humanigen to Present at the Jefferies 2019 Healthcare Conference (GBN) -  Jun 3, 2019   
    BURLINGAME, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered® monoclonal antibodies focused on chimeric antigen receptor T (CAR-T) cell therapy optimization and immuno-oncology, today announced that Dr. Cameron Durrant, the company’s Chairman and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference in New York, NY on Friday, June 7 at 11:00 a.m. Eastern Time.